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Abstract 
 
Background 
Imaging biomarkers for Alzheimer’s disease include medial temporal lobe atrophy (MTLA) depicted 
on CT or MRI, and patterns of reduced metabolism on FDG-PET. 
Aims 
To investigate whether MTLA on head CT predicts the diagnostic usefulness of an additional FDG-PET 
scan. 
Methods 
Participants had a clinical diagnosis of Alzheimer’s disease (AD; n=37), dementia with Lewy bodies 
(DLB; n=30), or were similarly aged controls (n=30).  We visually rated MTLA on coronally 
reconstructed CT scans and, separately and blind to CT ratings, abnormal appearances on FDG-PET 
scans.  
Results 
Using a pre-defined cutoff of MTLA >=5 on the Scheltens (0-8) scale, 0/30 controls, 6/30 DLB and 
23/30 AD had marked MTLA.  FDG-PET performed well for diagnosing AD vs DLB in the low MTLA 
group (sensitivity / specificity of 71%/79%), but in the high MTLA subjects, diagnostic performance of 
FDG-PET was not better than chance.  
Conclusions 
In  the presence of a high degree of MTLA, the most likely diagnosis is AD, and an FDG-PET scan will 
probably not provide significant diagnostic information. However, in cases without MTL atrophy, if 
the diagnosis is unclear, an FDG-PET scan may provide additional clinically useful diagnostic 
information.  
 
 Introduction 
 
Dementia affects around 35 million people worldwide, with numbers set to double in the next 30 
years. Increasingly, dementia is an international governmental priority, with early and accurate 
assessment and diagnosis placed at the heart of effective management pathways. The two main 
causes of degenerative dementia in older people are Alzheimer’s disease (AD), responsible for about 
65% of all cases, and dementia with Lewy bodies (DLB), responsible for 10-15% of cases in older 
people.  
Most international guidelines for assessment and diagnosis of dementia advocate the use of 
structural imaging (CT or MR) as a routine, both to exclude other intra-cerebral pathologies and 
determine the extent of regional brain atrophy 1-3.  Functional imaging methods such as FDG-PET and 
perfusion  SPECT are generally advocated as useful to clarify diagnosis when doubt remains after 
clinical assessment and structural imaging results.  
In the NIA revised diagnostic guidelines 4 proposed for AD clinical diagnosis, three imaging 
biomarkers for AD are proposed: medial temporal lobe atrophy (MTLA) on structural imaging; 
temporo-parietal hypometabolism of FDG-PET; and raised amyloid binding on amyloid-PET. The 
authors suggest that further research is needed “to prioritize biomarkers and to determine their 
value and validity in practice and research settings”. This is important, not only to enable the 
appropriate sequencing of biomarkers, but also from a health economic and patient perspective to 
ensure that investigations such as scans are only requested in situations where they will provide 
useful additional information to inform diagnosis, so that unnecessary cost and inconvenience to 
subjects is minimised.  
Modern multi-slice CT scanners allow assessment of MTLA comparable to T1 weighted MRI, 5 and 
assessment of MTLA with a visual rating scale 6 can be used to help distinguish AD from DLB 7. 
Although there are imaging biomarkers (e.g. FP-CIT 8) which have good diagnostic properties for the 
specific question of AD vs DLB, the initial clinical picture is frequently unclear, and scans with more 
general diagnostic ability such as FDG-PET are often requested in the diagnosis of dementia. The aim 
of this study was thus to investigate the additional diagnostic utility of FDG-PET following visual 
rating of MTLA on CT using the question of AD vs DLB as an exemplar. We hypothesised that for 
more severe MTL atrophy, PET would add little further diagnostic information. 
Methods 
 
Subjects 
Subjects were part of a study investigating the relative performance of FDG-PET vs perfusion SPECT 
in the diagnosis of AD and DLB. Main results from the study have been reported elsewhere  9. The 
study subjects were recruited prospectively from people aged over 60 with mild to moderate 
dementia (MMSE>12) referred to clinical services in North-East England, together with healthy 
controls of similar age, who were recruited from spouses of participants with dementia (N=9), along 
with those who had previously indicated a willingness to participate in research (N=22).  Subjects 
were recruited between June 2010 and June 2012. Control subjects had no symptoms of dementia, 
and patients met criteria for probable AD 10 or probable DLB 11. The study was approved by 
Newcastle and North Tyneside Research Ethics Committee (REF 09/H0906/88), and all participants 
(or nominated Independent Mental Capacity Advocate where participant lacked capacity) gave 
informed consent before participating. 
Clinical diagnosis was made by consensus between 3 experienced clinicians. Neither FDG-PET nor 
the  MTLA ratings from CT were used to inform the diagnosis; the only information regarding CT 
available to the diagnostic raters was from a previous clinical CT report providing information about 
the extent of any vascular pathology present and confirmation that no space occupying lesion was 
present.  All subjects had to have sufficient command of English and adequate visual and auditory 
acuity to allow cognitive and neuropsychological testing. Exclusion criteria were a) past history of 
alcohol or drug dependence; b) contraindications for FDG-PET scanning (e.g. inability to lie flat); c) 
fasting blood glucose level > 180 mg / dL.  All subjects meeting in/exclusion criteria who consented 
to take part were included in the study. We recruited 102 subjects, of whom three withdrew before 
completing both scans, and two were excluded due to scanner technical problems. A total of 37 
people with AD, 30 with DLB and 30 controls were successfully scanned with FDG-PET-CT.  
 
Subjects underwent detailed neuropsychiatric investigation including the Cambridge Cognitive 
Examination (CAMCOG)12, and the Rey Auditory Verbal Learning Test (AVLT) 13.  The Cornell scale for 
depression in dementia 14 was used to assess mood, and for dementia participants, we performed 
the Neuropsychiatric inventory (NPI)15, and the Clinician Assessment of Fluctuation (CAF) scale16. 
Parkinsonian motor features were assessed in all subjects using the motor subsection of the Unified 
Parkinson’s Disease Rating Scale (UPDRS III)17. 
Scanning 
Scans were performed at Newcastle University using a Siemens Biograph-40 Truepoint  FDG-PET-CT. 
CT scans were obtained using the 40 slice CT with 0.6mm slices, pitch 0.8, 200 mAs, 120 kV, imaging 
time 12s.  FDG-PET head scans were done over 10 min starting 30 min after iv administration of 250 
MBq F-18 FDG. Siemens software was used for iterative reconstruction with scatter and attenuation 
correction based on the CT scan data obtained immediately before the FDG-PET scan. 
 
Visual Rating  
The CT scans were viewed and rated separately, by different observers to the PET scans. All ratings 
were performed blind to diagnosis, and to the other images from the same subject. 
CT 
All CT scans were reconstructed as 3mm thick coronal sections oriented perpendicular to the long 
axis of the hippocampus by the same operator. Visual rating was performed with a standardized 
scale (Scheltens scale) to rate right and left MTLA separately 6. The scale rates atrophy on a 5-point 
scale (0 = absent, 1 = minimal, 2 = mild, 3 = moderate and 4 = severe) based on the height of the 
hippocampal formation and the width of the CSF spaces. For the purpose of analysis the left and 
right scores were summed to give a combined MTLA score (maximum score 8). All scans were 
assessed by consensus between two experienced raters (SC and RB) blinded to diagnosis. Figure 1 
shows example CT scans. 
 
FDG-PET 
Visual rating of the scans was performed blind to diagnosis and any clinical information by three 
imaging specialists (MJF, EDW, JJL) experienced in analysing and reporting nuclear medicine brain 
scans.  
To facilitate consistency in reporting, the imaging features associated with AD and DLB were set out 
in a document – key points were a) reduced uptake in precuneus and lateral parietal lobes in both 
AD and DLB; b) relative preservation of posterior cingulate in DLB; c) occipital loss more likely in DLB 
d) reduced uptake in temporal and frontal lobe more likely in AD. 
Each reader independently rated each scan on a 5-point scale for the degree of confidence in overall 
abnormality typical of dementia. For all scans not considered to be ‘definitely normal’, the match to 
AD or DLB was also rated, again using a 5-point scale.  After individual ratings were completed, the 
imaging team met to compare and review all their ratings and to produce a set of consensus ratings 
for each scan.  Each scan was also given a tripartite consensus classification of normal, AD or DLB.  
 
Quantitative analysis 
We also performed region of interest analysis on the PET scans. Full details are given elsewhere 9 but 
briefly, the PET scans were normalised to standard space in SPM8 (www.fil.ion.ucl.ac.uk/spm), and 
mean intensity within standard regions-of-interest (ROIs) were calculated for each scan. ROIs were 
taken from the AAL atlas 18 for medial temporal lobe, (hippocampus + parahippocampal gyrus) and 
medial occipital lobe (calcarine + lingual gyrus).  
Statistics 
Demographic and clinical rating data were analysed with SPSS 19.0 (SPSS, Chicago, IL).  Continuous 
variables were compared using independent Student t tests or ANOVA.  Chi squared tests were used 
to compare categorical data. ROC analysis was performed in SPSS. The diagnostic statistics 
(sensitivity etc) were calculated for AD vs DLB using R (http://www.r-project.org/ version  2.14.1) on 
those with a clinical diagnosis of dementia. For visual rating, the PET AD positive cases were those 
with consensus visual rating of definitely or probably AD, and PET AD negative cases were all other 
cases (visual rating of normal scan, unclear, probably or definitely DLB). For the ROI analysis, those 
with a medial temporal / occipital lobe uptake ratio of < 0.7  were classed as PET AD positive, 
otherwise negative. The diagnostic classification tables from which the statistics were calculated are 
available in the supplementary material. 
 
Results 
 
Table 1 shows the subject demographics. The groups were well matched for age, years of education, 
sex and duration of dementia. There were no significant differences between AD and DLB in 
CAMCOG score. As expected, the DLB group had more parkinsonian symptoms as demonstrated by 
significantly higher scores on the UPDRS, whilst the AD group had poorer memory performance on 
the Rey AVLT. The NPI score was not different between groups, but the DLB patients had more 
fluctuations of consciousness as measured by the CAF.   
All of the control subjects had a MTLA < 5. Table 2 shows the characteristics of the patients with 
dementia according to MTLA. Those subjects with high MTLA score were older than those with lower 
score, but there were no other significant differences. 
Figure 1 shows typical CT scans, and figure 2 shows the MTLA rating scores by group. In our previous 
examination of MTL atrophy, we found that a cut off of >=5 optimally distinguished AD from DLB and 
vascular dementia 7. With this cutoff, none of the control subjects, 6/30 DLB, and 23/37 AD had 
marked MTL atrophy. So a high MTLA was a good test for excluding non-dementia and most DLB 
cases, with a positive predictive value of 79%, but a lower sensitivity (62%) for detecting all AD cases. 
Table 3 presents the results of the FDG-PET visual rating consensus classification. PET performed 
generally very well at distinguishing controls from dementia at all levels of MTLA, with 24/30 (80%) 
of control scans being classed as normal and 61/67 (91%) of dementia cases as abnormal. For cases 
with MTLA < 5, visual rating of PET had a sensitivity / specificity of 71%/79% for diagnosis of AD vs 
DLB (table 4). However for those subjects with a  MTLA >=5, visual inspection of PET performed 
poorly for distinguishing  AD from DLB, with a sensitivity of 52%.  
Table 5 presents ROC analysis of AD vs DLB for both the visual rating (5 point scale) and the ratio of 
uptake in the medial temporal to occipital lobe, which we found to have good distinguishing ability 
in the whole cohort  9.  Visual rating and ROI analysis had similar values of AUC in both low and high 
MTLA groups. For the high MTLA group, the AUC was 0.69 for visual rating and 0.72 for ROI analysis, 
neither of which were significantly greater than chance (p>0.1). For low MTLA , both the visual rating 
and ROI analysis were significant  (p < 0.001) with AUC of 0.83 for visual rating, indicating good 
diagnostic ability. One factor influencing the less good diagnostic performance of PET at high MTLA 
is the increased variability, seen as higher SD for the AUC in the ROC analysis, and the ratio of MTL / 
occipital lobe  FDG uptake, (table 3)  where the variance is higher in the MTLA >= 5 group, 
significantly so in AD (SD 0.069 vs 0.032 , F22,13 = 0.22, p =0.006).  
 
Discussion 
 
Using a predetermined cutoff of >=5 on the MTL atrophy visual rating scale on 3mm slice CT for 
diagnosing AD (compared to DLB), we found a sensitivity of 62% and a specificity of 80%. The cutoff 
also excluded all of the normal control subjects and had good positive predictive value for AD (79%). 
Analysis of PET scans in the high MTLA subjects did not significantly improve diagnostic 
discrimination. In the group with low MTLA (14 AD, 23 DLB), PET performed well for identifying 
controls, and also had a sensitivity and specificity of 71% and 79% for distinguishing AD from DLB. 
Visual rating of the hippocampus can be performed fairly quickly by a trained person, with good 
reliability, and studies have shown it to be comparable to volumetric measurement for assessment 
of the hippocampus in AD 19. CT scans are quick and relatively cheap to perform, and are frequently 
done for suspected dementia to exclude space occupying lesions or vascular disease. Alternatively, if 
coronal MRI head scans are available, MTLA could be rated from those. We suggest that rating of 
MTLA should form a standard part of the examination report, since our data suggest that when 
there is a high degree of medial temporal lobe atrophy present, then the most likely diagnosis is 
Alzheimer’s disease, and it is unlikely that a FDG-PET scan will provide significant additional 
diagnostic information. In cases where MTL atrophy is absent or mild, and the diagnosis is unclear, 
then a FDG-PET scan may provide additional information. Our results are consistent with those of 
Ossenkoppole et al 20 who found that PET imaging contributed most to diagnosis when there was 
greater diagnostic uncertainty before considering the scan results. In the case where AD is still 
suspected, but there is absent MTL atrophy, testing levels of Aβ42 in CSF may be appropriate, as this 
has good sensitivity for detecting AD. 21  
 
Reduction in FDG uptake in the posterior cingulate cortex (PCC) is one of the characteristic features 
of AD. Previous work has shown that this is associated with disconnection between the PCC and the 
medial temporal lobe 22, 23. It is thus likely that the presence of severe MTLA on a CT scan will be 
accompanied by Alzheimer-like features on the FDG-PET scan due to this disconnection. This partly 
explains the relative lack of additional diagnostic information from FDG-PET in high MTLA. In the 
case of uncertain diagnosis in subjects with high MTLA, then a PET/SPECT scan examining a different 
neural system may be more useful (e.g. with an FP-CIT SPECT scan for detecting dopaminergic deficit 
associated with DLB 8).  
Subjects with high MTLA were older. Even in healthy subjects, MTLA tends to increase with age, 24 
there is an age related decrease in FDG-PET uptake, 25 and subjects with later onset AD have 
previously been reported to have less pronounced FDG deficits  26. The poorer diagnostic 
performance of FDG-PET in the high MTLA may thus have been in part due to lower and less distinct 
FDG uptake patterns in older subjects. It is also possible that the DLB subjects with high MTLA may 
have had some degree of AD pathology present. 
Caveats are that we only investigated AD and DLB in this study. Evaluation of MTLA in cases of mild 
cognitive impairment has good predictive value for development of AD 27 and studies are needed as 
to how best combine this with other biomarkers such as PET. Patients with fronto-temporal 
dementia commonly have hippocampal atrophy, and it is difficult to differentiate FTD from AD on 
the basis of MTLA  28-30. In the case of suspected FTD, more detailed examination of structural scans 
may help the diagnosis, since the pattern of structural atrophy is different to that seen in AD 31, 32. On 
FDG-PET scans, patients with FTD typically have greater frontal and temporal hypometabolism than 
AD 33 and studies have found generally good diagnostic differential ability for AD vs FTD 33-35 though 
with, in general, lower reported sensitivity (53-72%) for FTD than specificity (95-99%).  
We have previously shown that MTLA also discriminates AD from vascular dementia 7, and other 
studies have also found MTLA in VaD to be intermediate between controls and AD 36, 37 and hence 
the higher the MTLA score, the less likely there is VaD. Examination of MRI scans for presence of 
vascular  lesions is most likely to be of use to identify/exclude cases of VaD 38. 
We recruited control subjects from a similar demographic to the dementia participants. Controls had 
the highest mean years of education of any group, but there were no significant differences between 
the groups in age, sex or years of education. Our diagnosis was based on clinical assessment, without 
the aid of neuroimaging or CSF biomarkers, an approach which has been been validated in our group 
both against autopsy and other imaging markers and is a standard now accepted by regulatory 
authorities 8. Although there may be some mistaken clinical diagnoses, we believe that they are 
unlikely to affect our main conclusion that a FDG-PET scan will probably not help the diagnosis of AD 
in the presence of MTL atrophy on CT.  
Many countries, including the UK, have initiatives aimed at raising the profile of dementia and 
increasing the numbers diagnosed, with some research estimating that currently, less than half the 
people with dementia receive a formal diagnosis 39.  There will also be a substantial  increase in the 
numbers of patients with dementia over the next 40 years, due to increases in lifespan40. 
Neuroimaging services will be an important part of providing diagnoses to these increasing numbers. 
However, FDG-PET remains a relatively expensive option  and involves a rather lengthy procedure 
for the patient compared to a CT scan. Therefore, to maximise health care resources, and minimise 
unnecessary investigations for people with dementia, FDG-PET will have to be used only as part of 
an evidence based diagnostic pathway. Based on our results, a suggested algorithm for considering  
neuroimaging, dependent on both the CT results and the clinical question, is presented in Figure 3. 
Future work should seek to incorporate other imaging biomarkers into this algorithm, for example 
amyloid-PET. 
 
Acknowledgments 
We thank the National Institute for Health Research for funding this study which was also supported 
by the NIHR Biomedical Research Centre and Lewy-body Dementia Biomedical Research Unit 
awarded to Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, and the 
NIHR Biomedical Research Centre and Biomedical Research Unit in Dementia awarded to the 
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. We thank 
the Dementia and Neurodegenerative Diseases Research Network (DeNDRoN) for valuable support 
with clinical recruitment. 
  
Authors 
Michael J Firbank, PhD 1, 2, Jim Lloyd, PhD 2 , David Williams, PhD 1, Robert Barber, MD1 
Sean J Colloby, PhD 1, Nicky Barnett, BSc 1,  Kirsty Olsen, BSc 1, Christopher Davison, 
MRCPsych 1, Cam Donaldson, PhD 3,4, Karl Herholz, PhD 5, John T O’Brien, DM 6, 1, 
 
Authors’ affiliations 
1 Institute for Neuroscience, Campus for Ageing and Vitality, Newcastle University, 
Newcastle upon Tyne, UK 
2 Nuclear Medicine Department, Newcastle upon Tyne Hospitals NHS Foundation 
Trust, Newcastle upon Tyne, UK 
3 Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK  
4 Yunus Centre, Glasgow Caledonian University, Glasgow, UK  
5 Wolfson Molecular Imaging Centre, Institute of Brain, Behaviours and Mental Health, 
University of Manchester, Manchester, UK 
6  Department of Psychiatry, University of Cambridge School of Clinical Medicine, Box 
189, Level E4,  Cambridge Biomedical Campus, Cambridge, UK 
 
Conflicts of interest 
MF reports grants from National Institute for Health Research, KH reports grants and 
personal fees from Lilly/Avid Radiopharmacuticals, personal fees from GE Healthcare, 
Cytox, and Elan, other from Herholz Consulting GmbH, outside the submitted work, JOB 
report grants and other from GE Healthcare, grants and other from Lilly, other from Bayer 
Healthcare, other from TauRx, other from Cytox, outside submitted work.  
The study sponsor played no role in study design and the collection, analysis, and 
interpretation of data and the writing of the article and the decision to submit it for 
publication. The researchers are independent from funders and sponsors and have full 
access to all the data. 
 
  
 Tables 
 
Table 1 Subject demographics. Values are mean (SD) [range] 
 
 Control (N=30) AD (N=37) DLB (N=30)  
Age 76.3 (6.6) 75.8 (7.6) 76.5 (5.8) F2,94= 0.11, p=0.9 
Female:Male  10:20 15:22 7:23 Χ2= 2.2, p=0.3  
Education (years) 11.9 (2.8) 11.5 (2.6) 10.6 (2.3) F2,94=1.97, p=0.15 
Duration of dementia 
(months) 
- 44.1 (23.2)  
[12 – 132] 
38.1 (27.3)  
[9 – 120] 
t65 = 0.97, p=0.3 § 
MMSE 28.9 (1.1)       
[26 – 30]  
20.9 (3.7)     
[15 – 28] 
21.8 (4.2)  
[14 – 28] 
t65 = -0.95, p=0.3 § 
CAMCOG 98.4 (4.0) 71.5 (11.7) 72.6 (13.1) t65 = -0.35, p=0.7 § 
Rey total  70.3 (12.3) 25.1 (9.6) 33.4 (12.1) t65 = -3.1, p=0.002 § 
Cornell 1.8 (1.8) 4.5 (2.8) 8.1 (3.8) F2,94 = 35.9, p<0.001 
CAF total - 1.5 (2.5) 6.0 (4.7) t64 = -4.7, p<0.001 § 
NPI total -  14.8 (14.6) 19.7 (15.6) t64 = -1.3, p=0.2  § 
UPDRS 2.6 (2.7) 3.7 (3.3) 25.5 (11.9) F2,94= 104, p<0.001 
MTLA >=5 0 (0%) 23 (62 %) 6 (20%) Χ2 = 32.6; p<0.001 
 
 
  
Table 2 Subject demographics by MTLA for the patients with dementia  
 AD  
MTLA < 5 
(N=14) 
AD  
MTLA >=5 
(N=23) 
 DLB  
MTLA < 5 
(N=24) 
DLB  
MTLA >=5  
(N=6) 
 
Age 71.0 (7.1) 78.7 (6.4) T=3.3,p=0.002 75.3 (5.4) 81.0 (5.7) T=2.3,p=0.031 
Female:Male  7:7 8:15 X2=0.8, p=0.5  5:19 2:4 X2=0.4,p=0.6 
Duration of 
dementia 
(months) 
39.7 (17) 
 
46.7 (26) T=0.9,p=0.4 38.0 (26)  38.0 (35) T=0.0,p=1.0 
MMSE 21.1 (4.2) 20.8 (3.5) T=-0.3,p=0.8 22.5 (4.0) 19.0 (3.8) T=-1.9,p=0.06 
CAMCOG 74.0 (12) 70.0 (11) T=-1.0,p=0.4 74.1 (11) 66.5 (19) T=-1.3,p=0.2 
UPDRS 3.6 (4.1) 3.7 (2.7) T=0.2, p=0.9 24.3 (12) 30.0 (11) T=1.0,p=0.3 
 
 
 
Table 3 Consensus visual rating from 3 observers of PET scans by different groups and MTL atrophy 
severity. Values in shaded cells represent correct diagnoses. Ratio of FDG-PET uptake in medial 
temporal lobe to occipital lobe ROIs also shown. 
  PET visual rating consensus PET MTL / Occipital 
ROI ratio mean (SD) 
MTLA 
 Def/Prob 
normal  
Def/ Prob 
AD 
Unclear 
AD v DLB 
Def/ Prob DLB  
 AD      
0-4 14 1 (7%) 10 (71%) 3 (21%) 0 0.647 (0.032) 
5-8 23 1 (4%) 12 (52%) 6 (26%) 4 (17%) 0.631 (0.069) 
       
 DLB      
0-4 24 4 (17%) 5 (21%) 1 (4%) 14 (58%) 0.751 (0.080) 
5-8 6 0  1 (17%) 3 (50%) 2   (33%) 0.711 (0.123) 
       
 Controls      
0-4 30 24 (80%) 1 (3%) 3 (10%) 2 (7%) 0.681 (0.039) 
5-8 0      
 
 
 
 
Table 4. Diagnostic statistics for identifying AD (vs DLB). 95% confidence interval in brackets. PET ROI is the MTL / occipital uptake ratio. The CT & PET visual 
rating figures are obtained by following the diagnostic flowchart in figure 3, i.e. an AD diagnosis is given via either MTL atrophy on CT, or AD positive FDG-
PET scan following normal MTL on CT. 
 
Sensitivity Specificity 
Positive 
Predictive Value 
Negative 
Predictive Value Accuracy 
Likelihood ratio 
for positive result 
CT rating  0.62 (0.45-0.77) 0.80 (0.61-0.92) 0.79 (0.60-0.91) 0.63 (0.46-0.78) 0.70 (0.58-0.80)  3.11 (1.46-6.64) 
     
 
 PET visual rating, all cases 0.59 (0.42-0.75) 0.80 (0.61-0.92) 0.79 (0.59-0.91) 0.62 (0.45-0.76) 0.69 (0.56-0.79) 2.97 (1.39-6.38) 
CT <5, PET visual rating 0.71 (0.42-0.90) 0.79 (0.57-0.92) 0.67 (0.39-0.87) 0.83 (0.60-0.94) 0.76 (0.59-0.88) 3.43 (1.47-8.00) 
CT >=5, PET visual rating 0.52 (0.31-0.73) 0.83 (0.36-0.99) 0.92 (0.62-1.00) 0.31 (0.12-0.59) 0.59 (0.39-0.76) 3.13 (0.50-19.5) 
CT & PET visual rating 0.89 (0.74-0.96) 0.63 (0.44-0.79) 0.75 (0.59-0.86) 0.83 (0.60-0.94) 0.78 (0.65-0.87) 2.43 (1.50-3.94) 
     
 
 PET MTL/Occipital ROI  0.89 (0.74-0.96) 0.80 (0.61-0.92) 0.85 (0.69-0.94) 0.86 (0.66-0.95) 0.85 (0.74-0.92) 4.46 (2.16-9.20) 
CT <5, PET ROI 0.93 (0.64-1.00) 0.83 (0.62-0.95) 0.76 (0.50-0.92) 0.95 (0.74-1.00) 0.87 (0.71-0.95) 5.57 (2.25-13.8) 
CT >=5, PET ROI 0.87 (0.65-0.97) 0.67 (0.24-0.94) 0.91 (0.69-0.98) 0.57 (0.2-0.88) 0.83 (0.64-0.93) 2.61 (0.83-8.18) 
CT & PET ROI 0.97 (0.84-1.00) 0.67 (0.47-0.82) 0.78 (0.63-0.89) 0.95 (0.74-1.00) 0.84 (0.72-0.91) 2.92 (1.75-4.86) 
 
  
Table 5 Values from ROC analysis based on the consensus rating and the ratio of regions of interest 
in the occipital / medial temporal lobe. Values are AUC (SE) and sensitivity/specificity for identifying 
AD. 
MTL 
rating 
PET AD vs DLB  
Consensus visual rating  
(N=67) 
 
PET ROI MTL/Occipital 
(N=67) 
 AUC (SE) AUC (SE) 
0-4 0.83 (0.07)*** 0.85 (0.07) *** 
5-8 0.69 (0.13)  0.72 (0.15)  
   
*** p<0.001 
  
 Figure 1 CT of DLB with (left) high (MTLA=8) and (right) low (MTLA=2) MTLA score. Greater medial 
temporal atrophy (arrowed) is clearly visible in the left hand scan. 
 
   
  
Figure2 Medial temporal lobe atrophy rating (L+R) for all subjects. Horizontal bar shows group 
means. 
 
 Figure 3 Evidence based imaging algorithm for FDG PET use 
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AD = Alzheimer’s disease; DLB = Dementia with Lewy bodies; FTD = Fronto-temporal 
dementia; FP-CIT = SPECT with FPCIT (dopamine transporter) ligand; CT = computed 
tomography; FDG-PET = fluorodeoxyglucose PET (positron emission tomography); VaD = 
Vascular Dementia; Aβ Amyloid-beta; CSF = Cerebrospinal fluid  
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Is there marked medial temporal atrophy? 
Yes          No 
 
Suspected AD following clinical assessment 
 
Consider FDG-PET 
Consider MRI 
Consider FP-CIT 
Is there sufficient confidence to make clinical diagnosis 
       No                  Yes
   
Make 
diagnosis 
 
To: 
Confirm / exclude DLB 
Confirm / exclude AD 
Confirm / exclude FTD  
Confirm / exclude VaD 
Consider Aβ CSF 
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